Samir Kaul is a founding partner and managing director at Khosla Ventures whose public portfolio spans artificial intelligence, health, sustainability, food, and advanced technology. The evidence supports a cross-sector investment role and a long-running partnership at the firm. It does not support crediting Kaul alone with Khosla Ventures’ original OpenAI decision, calculating a personal return, or claiming that a $50 million position became exactly $15 billion.

As of September 13, 2026, the Khosla Ventures biography lists Kaul’s titles and portfolio focus. That is the firm’s self-description. A public New Jersey Division of Investment memorandum independently describes Khosla Ventures as founded by Vinod Khosla with Kaul and David Weiden and identifies Kaul with the firm’s AI sector work. The memo was written for an institutional investment decision and is dated evidence, not a guarantee of later performance.

The most useful way to assess Kaul is through portfolio construction: how a venture firm finances uncertain technical programs, reserves capital for winners, and prevents a few marked-up companies from obscuring fund-level risk.

The short answer: Kaul’s role is broader than one famous investment

Khosla Ventures’ official page associates Kaul with companies across computational biology, diagnostics, robotics, materials, food, enterprise software, and AI. That breadth suggests a search for technical platforms that can open new markets, not a narrow software-only strategy.

Kaul described part of his background and investing approach in a 2020 interview published by Khosla Ventures. Because the firm hosts the transcript, it is a primary source for what he said, not independent validation of the resulting investments. It shows an investor interested in technical teams and markets where scientific or engineering progress changes the business boundary.

Cross-sector investing can be an advantage when expertise transfers. Machine learning can affect drug discovery, industrial systems, agriculture, and software. It can also create shallow pattern matching if an investor assumes the same scaling laws, sales cycles, or capital needs apply everywhere. The quality of Kaul’s strategy depends on sector-specific diligence beneath the shared technology thesis.

That means asking different questions by company type. A software agent needs reliable task completion, security, and attractive inference economics. A therapeutic company needs biological evidence, clinical milestones, regulatory strategy, and enough capital to reach them. A food or materials company needs manufacturing yield, input supply, unit economics, and customer qualification. “Deep tech” is not a single operating model.

The OpenAI claim needs correction

Khosla Ventures publicly says Vinod Khosla led the firm’s $50 million OpenAI investment in January 2019. The available firm biographies do not establish that Kaul personally led it. Kaul may have contributed as a partner, but contribution cannot be reconstructed from public silence.

The original article also converted the investment into a precise $15 billion value and 300-times return. That calculation is not supportable from public sources. OpenAI’s October 2025 structure disclosure groups current and former employees and outside investors into a combined 47 percent ownership category. It does not disclose Khosla Ventures’ stake, dilution, security terms, follow-on purchases, transfers, or realized proceeds.

Fund returns also differ from a company’s headline valuation. A credible calculation needs the acquisition cost and dates of every security, the ownership after dilution, the allocation among funds, cash distributions, fees, carry, and a defensible value for illiquid shares. Without those inputs, the correct label is “undisclosed.”

This is not a semantic objection. Venture portfolios can show high gross paper gains while returning much less cash to limited partners. The timing and liquidity of outcomes matter.

Reserves and opportunity funds shape the result

Early-stage firms face a recurring allocation problem. Investing pro rata in every company wastes capital on weak performers; declining every follow-on can surrender ownership in rare winners. The decision depends on updated evidence and price.

In January 2022, Axios reported that Khosla Ventures raised a $557 million opportunities fund. The report quotes Kaul explaining that the vehicle would support pro rata investment in later rounds. This is a named, external account of the fund’s purpose. It does not show how every investment performed.

An opportunity fund can preserve ownership without forcing an early-stage vehicle to concentrate beyond its mandate. It can also create conflicts:

  • Which vehicle receives a scarce allocation?
  • How is price fairness assessed when several affiliated funds invest?
  • Does extra capital follow operating evidence or protect an earlier mark?
  • Are limited partners shown performance with and without cross-fund transfers?

Institutional investors should examine these questions in partnership agreements, advisory committee records, valuation policy, and fund cash flows. A media story about a winning company cannot substitute for that work.

Portfolio evidence should be measured at three levels

The cleanest way to evaluate Kaul’s strategy separates company, deal, and fund performance.

Company performance asks whether a business creates durable value: scientific milestones, product adoption, retention, margins, regulatory progress, or cash generation. These measures vary by sector.

Deal performance asks what the fund paid, how much ownership it retained, what it received in distributions, and what value remains unrealized. A successful company can still be a mediocre deal if entry price, dilution, or follow-on allocation is poor.

Fund performance aggregates all deals after fees and carry and adjusts for timing. Limited partners need distributed-to-paid-in capital, total value to paid-in capital, and net internal rate of return by vintage. They also need concentration and loss ratios to see how much a few companies drive the result.

The New Jersey memorandum provides a rare public window into institutional diligence and historical figures as of its reporting date. Those data should be read with the document’s valuation date, scope, and assumptions. They should not be extrapolated into a current personal or firm-wide wealth number.

Cross-sector technical diligence

Kaul’s public portfolio makes a useful case study in how evidence changes across domains.

For AI infrastructure and software, diligence should reproduce model benchmarks, test customer retention, separate revenue from subsidized usage, and model inference cost under realistic load. For biology, it should distinguish in-silico prediction from wet-lab validation and clinical evidence. For hardware, it should inspect yield, reliability, supplier concentration, and manufacturing capital. For climate and food, it should compare lifecycle effects and unit economics at commercial scale, not just pilot output.

Across all categories, the common questions are:

  1. What technical milestone would reduce the largest uncertainty?
  2. Who independently reproduced the result?
  3. How much capital and time are required to reach the next decisive test?
  4. What evidence would cause the investor to stop financing the thesis?
  5. If the technology works, who pays and why does the company retain value?

This framework makes tolerance for failure disciplined rather than romantic. A failed experiment can be informative. Repeatedly financing a thesis after contrary evidence is not the same thing.

A scorecard for Kaul’s public strategy

Because complete fund data are private, outsiders should keep conclusions bounded. The public record can support a process scorecard:

  • breadth and relevance of technical expertise around a deal;
  • follow-on decisions tied to disclosed milestones;
  • reserve discipline and vehicle allocation;
  • realized distributions, not only valuation marks;
  • failure analysis and time to stop;
  • governance practices where the firm holds board influence;
  • accuracy of public forecasts over stated time horizons.

Founders can add another dimension: whether the firm provides useful recruiting, technical, commercial, and financing support without forcing a generic scaling playbook onto a sector with different constraints.

None of these measures requires private biography or speculative wealth. They evaluate the work.

What remains unknown

Public sources do not disclose Kaul’s personal economics, ownership in the management company, carry allocation, individual net worth, or the precise division of decision-making among Khosla Ventures partners. They do not establish his individual contribution to the 2019 OpenAI investment.

OpenAI’s current aggregate ownership disclosure is insufficient to calculate Khosla Ventures’ stake or return. Likewise, selected company exits and current portfolio valuations cannot establish the net performance of funds associated with Kaul.

The supportable conclusion is that Kaul helped build Khosla Ventures and has a documented cross-sector investing role, including AI. His strategy should be judged by milestone quality, ownership discipline, realizations, and net portfolio outcomes. The OpenAI position is relevant evidence of early exposure, but its precise value and Kaul’s personal benefit remain private.

Source and correction note

This revision removes unsupported claims of a $15 billion OpenAI position, a 300-times return, personal wealth, and sole responsibility for the OpenAI investment. It replaces private-scene narration with the firm’s biography, a public institutional-investment memorandum, a named interview, Axios reporting, and OpenAI’s ownership disclosure. Firm statements and unavailable economics are labeled explicitly.